Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06740812 · ClinicalTrials.gov registry record · Phase 4
Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide
A Phase 4 study, sponsored by Montefiore Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 212
- Enrollment target
NCT06740812 is a Phase 4 study that has not yet begun recruiting, run by Montefiore Medical Center. The registered enrollment target is 212 participants.
The verdict
NCT06740812, a Phase 4 study, has not yet begun recruiting, sponsored by Montefiore Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 212 participants
- Enrollment target
Study Summary
The study team proposes a double-blind, comparative effectiveness, randomized controlled trial (RCT) to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic metoclopramide. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in emergency departments (EDs). Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time.
Interventions
- DRUG Fosaprepitant for Injection
- DRUG Metoclopramide Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2026-12 |
| Est. Completion | 2027-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06740812
The ClinicalTrials.gov registry entry for NCT06740812 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fosaprepitant for Injection is the first listed.
NCT06740812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06740812 about?
NCT06740812 is a clinical study titled "Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide". The study team proposes a double-blind, comparative effectiveness, randomized controlled trial (RCT) to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic metoclopramide. Fosaprepitant and its active m...
What is the current status of trial NCT06740812?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 212 participants. The study started on 2026-12. Estimated completion is 2027-09.
What interventions are being tested in trial NCT06740812?
The interventions under investigation include: Fosaprepitant for Injection (DRUG), Metoclopramide Injection (DRUG).
Who is sponsoring clinical trial NCT06740812?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.